Lead optimization at C-2 and N-3 positions of thiazolidin-4-ones as HIV-1 non-nucleoside reverse transcriptase inhibitors

Bioorganic and Medicinal Chemistry

Volumn 19, Issue 22, 2011, Pages 6919-6926

  Murugesan, Vanangamudi ^a   Tiwari, Vinay S ^a   Saxena, Reshu ^a   Tripathi, Rajkamal ^a   Paranjape, Ramesh ^b   Kulkarni, Smita ^b   Makwana, Nandini ^b   Suryawanshi, Rahul ^b   Katti, Seturam B ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

^b NATIONAL AIDS RESEARCH INSTITUTE   (India)

Author keywords

Anti HIV 1 activity; HIV 1 reverse transcriptase; NNRTIs; Thiazolidin 4 ones

Indexed keywords

2 (2 CHLORO 6 FLUOROPHENYL) 3 (5 METHYLISOXAZOL 3 YL)THIAZOLIDIN 4 ONE; 2 (2,6 DICHLOROPHENYL) 3 (5 METHYLISOXAZOL 3 YL)THIAZOLIDIN 4 ONE; 2 (2,6 DIFLUOROPHENYL) 3 (5 METHYLISOXAZOL 3 YL)THIAZOLIDIN 4 ONE; 2 (3,5 DIBROMOPYRIDIN 4 YL) 3 (4,6 DIMETHYLPYRIDIN 2 YL)THIAZOLIDIN 4 ONE; 2 (3,5 DIBROMOPYRIDIN 4 YL) 3 (6 METHYLPYRIDIN 2 YL)THIAZOLIDIN 4 ONE; 2 (3,5 DICHLOROPYRIDIN 4 YL) 3 (4,6 DIMETHYLPYRIDIN 2 YL)THIAZOLIDIN 4 ONE; 2 (3,5 DICHLOROPYRIDIN 4 YL) 3 (6 METHYLPYRIDIN 2 YL)THIAZOLIDIN 4 ONE; 3 (5 BROMO 4,6 DIMETHYLPYRIDIN 2 YL) 2 (2 CHLORO 6 FLUOROPHENYL)THIAZOLIDIN 4 ONE; 3 (5 BROMO 4,6 DIMETHYLPYRIDIN 2 YL) 2 (2,6 DICHLOROPHENYL)THIAZOLIDIN 4 ONE; 3 (5 BROMO 4,6 DIMETHYLPYRIDIN 2 YL) 2 (3,5 DIBROMOPYRIDIN 4 YL)THIAZOLIDIN 4 ONE; 3 (5 BROMO 4,6 DIMETHYLPYRIDIN 2 YL) 2 (3,5 DICHLOROPYRIDIN 4 YL)THIAZOLIDIN 4 ONE; 3 (5 BROMO 6 METHYLPYRIDIN 2 YL) 2 (3,5 DIBROMOPYRIDIN 4 YL)THIAZOLIDIN 4 ONE; 3 (5 BROMO 6 METHYLPYRIDIN 2 YL) 2 (3,5 DICHLOROPYRIDIN 4 YL)THIAZOLIDIN 4 ONE; 3 (5 TERT BUTYLISOXAZOL 3 YL) 2 (2 CHLORO 6 FLUOROPHENYL)THIAZOLIDIN 4 ONE; 3 (5 TERT BUTYLISOXAZOL 3 YL) 2 (2,6 DICHLOROPHENYL)THIAZOLIDIN 4 ONE; 3 (5 TERT BUTYLISOXAZOL 3 YL) 2 (2,6 DIFLUOROPHENYL)THIAZOLIDIN 4 ONE; 3 [6 CHLORO 2 (METHYLTHIO)PYRIMIDIN 4 YL] 2 (2 CHLORO 6 FLUOROPHENYL)THIAZOLIDIN 4 ONE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; THIAZOLIDIN 4 ONE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; BIOISOSTERISM; CELL ASSAY; CHEMICAL MODIFICATION; CHEMICAL STRUCTURE; CONFERENCE PAPER; CONTROLLED STUDY; CYTOTOXICITY; DRUG BINDING SITE; DRUG DESIGN; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; MOLECULAR DOCKING; MOLECULAR MODEL; STRUCTURE ACTIVITY RELATION; VIRUS STRAIN;

ANTI-HIV AGENTS; DRUG DESIGN; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; REVERSE TRANSCRIPTASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 80055016796     PISSN: 09680896     EISSN: 14643391     Source Type: Journal    
DOI: 10.1016/j.bmc.2011.09.018     Document Type: Conference Paper

References (20)

1. H. Jonckheere, J. Anné, and E.D. Clercq Med. Res. Rev. 20 2000 129
2. E.D. Clercq Int. J. Antimicrob. Agents 33 2009 307
3. R.K. Rawal, Y.S. Prabhakar, S.B. Katti, and E.D. Clercq Bioorg. Med. Chem. 13 2005 6771
4. R.K. Rawal, R. Tripathi, S.B. Katti, C. Pannecouque, and E.D. Clercq Bioorg. Med. Chem. 15 2007 1725
5. R.K. Rawal, R. Tripathi, S.B. Katti, C. Pannecouque, and E.D. Clercq Bioorg. Med. Chem. 15 2007 3134
6. R.K. Rawal, R. Tripathi, S.B. Katti, C. Pannecouque, and E.D. Clercq Med. Chem. 3 2007 355
7. R.K. Rawal, R. Tripathi, S.B. Katti, C. Pannecouque, and E.D. Clercq Eur. J. Med. Chem. 43 2008 2800
8. R.K. Rawal, R. Tripathi, S. Kulkarni, R. Paranjape, S.B. Katti, C. Pannecouque, and E.D. Clercq Chem. Biol. Drug Des. 72 2008 147
9. A. Rao, J. Balzarini, A. Carbone, A. Chimirri, E.D. Clercq, A.M. Monforte, P. Monforte, C. Pannecouque, and M. Zappala IL. Farmaco 59 2004 33
10. A. Rao, A. Carbone, A. Chimirri, E.D. Clercq, A.M. Monforte, M. Pietro, C. Pannecouque, and M. Zappala IL. Farmaco 57 2002 747
11. Y.S. Prabhakar, V.R. Solomon, R.K. Rawal, M.K. Gupta, and S.B. Katti QSAR Comb. Sci. 23 2004 234
12. Y.S. Prabhakar, R.K. Rawal, M.K. Gupta, V.R. Solomon, and S.B. Katti Comb. Chem. High Throughput Screening 8 2005 431
13. R.K. Rawal, Y. Prabhakar, and S.B. Katti QSAR Comb. Sci. 26 2007 398
14. V. Murugesan, Y.S. Prabhakar, and S.B. Katti J. Mol. Graphics Modell 27 2009 735
15. H. Chen, J. Bai, L. Jiao, Z. Guo, Q. Yin, and X. Li Bioorg. Med. Chem. 17 2009 3980
16. L.M. Lima, and E.J. Barreiro Curr. Med. Chem. 12 2005 23
17. G.M. Morris, D.S. Goodsell, R.S. Halliday, R. Huey, W.E. Hart, R.K. Belew, and A.J. Olson J. Comput. Chem. 19 1998 1639
18. K. Das, J.D. Bauman, A.D.J. Clark, Y.V. Frenkel, P.J. Lewi, A.J. Shatkin, S.H. Hughes, and E. Arnold Proc. Natl. Acad. Sci. U.S.A. 105 2008 1466
19. Reverse Transcriptase Assay, Colorimetric kit, Roche Diagnostics GmbH, Roche Applied Science, Sandhofer Strasse 116, D-68305 Mannheim, Germany.
20. A.R. Geonnotti, M. Bilska, X. Yuan, C. Ochsenbauer, T.G. Edmonds, J.C. Kappes, H.X. Liao, B.F. Haynes, and D.C. Montefiori AIDS Res. Hum. Retroviruses 26 2010 279